CRNX

Business Context and Reporting Period

This Form 8-K, dated August 19, 2026, is filed by Crinetics Pharmaceuticals, Inc. (CRNX) to provide supplemental disclosures regarding its proposed acquisition by Vertex Pharmaceuticals Incorporated. The filing addresses shareholder lawsuits and demand letters alleging material omissions in the Proxy Statement for the Special Meeting scheduled for August 28, 2026. The Merger Agreement, entered into on July 6, 2026, provides for Crinetics to be acquired for $85.00 per share in cash, valuing the equity at approximately $10 billion.

Key Financial Metrics and Valuation

While this filing does not report historical GAAP financial results, it discloses critical valuation metrics and forward-looking projections used to justify the transaction price:

• Merger Consideration: $85.00 per share in cash.
• Unaffected Stock Price: $42.23 per share (as of July 2, 2026).
• Net Cash Position: Approximately $1,209 million as of June 30, 2026.
• Net Operating Loss (NOL) Carryforwards: Approximately $862 million as of December 31, 2025.
• Financial Advisor Fees:
  • J.P. Morgan: Estimated $69.4 million (approx. $2.0 million paid upfront, remainder contingent).
  • Leerink Partners: Estimated $60.8 million (approx. $2.0 million paid upfront, remainder contingent).

Management Forecasts (Risk-Adjusted)

Projections provided to financial advisors indicate the following trajectory (in millions):

Material Changes and Litigation

The primary material event is the filing of three shareholder complaints (McDaniels v. Crinetics, Clark v. Crinetics, and Drulias v. Bedrosian) and several demand letters alleging that the Proxy Statement contained false or misleading statements. In response, Crinetics voluntarily supplemented the Proxy Statement with additional data, including:

• Board Deliberations: Disclosure that the Board discussed a pending derivative action (Solak v. Wierenga) regarding director compensation but deemed it immaterial relative to the $10 billion transaction value.
• Valuation Methodologies: Detailed breakdowns of J.P. Morgan and Leerink Partners' analyses, including Public Trading Multiples, Selected Transactions, and Discounted Cash Flow (DCF) models.
• Implied Value Ranges:
  • J.P. Morgan DCF: $68.25 to $86.00 per share.
  • J.P. Morgan Public Multiples: $30.75 to $95.00 per share.
  • J.P. Morgan Precedent Transactions: $47.75 to $84.75 per share.

Guidance, Outlook, and Risks

Management Commentary: The Board of Directors continues to unanimously recommend a "FOR" vote on the Merger Proposal, the executive compensation advisory vote, and the adjournment proposal. The Board denies all allegations in the lawsuits and demand letters, stating the supplemental disclosures are made voluntarily to avoid delay and provide additional information, not as an admission of merit.

Outlook: The transaction is expected to accelerate Vertex's revenue growth, with potential for more than $5 billion in annual revenue from Crinetics assets. The deal is projected to become accretive to Vertex's non-GAAP operating income in 2029.

Risks and Contingencies:

• Termination Risks: The Merger Agreement may be terminated if closing conditions are not met, potentially triggering termination fees.
• Integration Risks: Uncertainty regarding the successful integration of businesses and retention of key personnel.
• Regulatory and Litigation: Risks related to regulatory approvals and the outcome of pending shareholder lawsuits.
• Forward-Looking Statements: Actual results may differ materially from projections due to drug development risks and market conditions.

Investor Verification Checklist

• Verify the status of the three shareholder lawsuits filed in New York and California and any potential impact on the August 28, 2026, Special Meeting.
• Review the definitive Proxy Statement (filed July 31, 2026) to understand the full context of the supplemental disclosures regarding the Board's decision-making process.
• Assess the sensitivity of the valuation to the "risk-adjusted" revenue forecasts, particularly the assumption of $1,057 million in 2030 revenue.
• Confirm the terms of the $10 billion acquisition, specifically the $85.00 per share cash price and the absence of equity rollover for shareholders.
• Monitor for any additional demand letters or complaints that may arise prior to the shareholder vote.